2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide,
GSK 212,
GSK 2126458,
GSK-212,
GSK-2126458,
GSK212,
GSK2126458,
GSK2126458,
1086062-66-9,
Omipalisib,
GSK-2126458,
GSK 2126458,
2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide,
UNII-1X8F5A3NA0,
Omipalisib (GSK2126458, GSK458),
2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide,
2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide,
1X8F5A3NA0,
GSK458,
C25H17F2N5O3S,
Omipalisib [USAN:INN],
GSK-212,
2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide,
PubChem22430,
Omipalisib (USAN/INN),
cc-65,
MLS006011258,
Omipalisib; GSK2126458,
SCHEMBL623194,
GTPL8974,
CHEMBL1236962,
CHEBI:95093,
DTXSID10148604,
EX-A003,
GSK-458,
SYN1126,
3l08,
CGBJSGAELGCMKE-UHFFFAOYSA-N,
HMS3656D09,
AOB87781,
BCP02252,
ABP000103,
BDBM50145416,
MFCD16038929,
Omipalisib pound GSK-458 pound(c),
s2658,
ZINC43208634,
AKOS015904655,
CS-0085,
DB12703,
QC-7243,
RL00368,
SB16572,
NCGC00250408-01,
NCGC00250408-05,
4CA-0591,
AC-28458,
AK-55828,
AN-17171,
AS-16266,
BC638723,
Benzenesulfonamide, 2,4-difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-,
GSK2126458 (GSK458),
HY-10297,
SC-85404,
SMR004703011,
AB0033735,
FT-0669061,
SW219502-1,
X7449,
KS-00000635,
A25172,
D10718,
W-5626,
J-507217,
I14-17004,
2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-yl-6-quinolyl)-3-pyridyl]benzenesulfonamide,
N-[2-Methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide,
2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide,
ZIG,
D03EZE,
GSK212,
GSK 212,
A8556,
A11035,
C561454,
1-Propanone,1-[1-[(4-methoxyphenyl)methyl]-1H-pyrazol-4-yl]-,
Omipalisib, 98%, a highly selective and potent inhibitor of PI3K - 10MG 10mg,
1065062-66-9,
1105039-60-8,
2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide,